129 related articles for article (PubMed ID: 29599449)
1. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Günes C; Wezel F; Southgate J; Bolenz C
Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
[TBL] [Abstract][Full Text] [Related]
2. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
[TBL] [Abstract][Full Text] [Related]
3. Activating Telomerase
Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
[TBL] [Abstract][Full Text] [Related]
4. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
[No Abstract] [Full Text] [Related]
5. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity: a biomarker of cell proliferation, not malignant transformation.
Belair CD; Yeager TR; Lopez PM; Reznikoff CA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13677-82. PubMed ID: 9391085
[TBL] [Abstract][Full Text] [Related]
8. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
Zheng L; Chen H; Zhao J; Roy-Chowdhuri S; Kamat AM; Alhalabi O; Gao J; Siefker-Radtke A; Hansel DE; Czerniak B; Guo CC
Hum Pathol; 2024 Jun; 148():1-6. PubMed ID: 38679207
[TBL] [Abstract][Full Text] [Related]
9. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Zvereva M; Hosen MI; Forey N; Sheikh M; Kannengiesser C; Ba I; Manel A; Vian E; Le Calvez-Kelm F
Methods Mol Biol; 2023; 2684():213-228. PubMed ID: 37410237
[TBL] [Abstract][Full Text] [Related]
10. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
Wan S; Liu X; Hua W; Xi M; Zhou Y; Wan Y
Bioengineered; 2021 Dec; 12(1):1495-1504. PubMed ID: 33938397
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
13. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
14. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
[TBL] [Abstract][Full Text] [Related]
15. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
16. Sleeping beauty: awakening urothelium from its slumber.
Balsara ZR; Li X
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F732-F743. PubMed ID: 28122714
[TBL] [Abstract][Full Text] [Related]
17. Highly recurrent TERT promoter mutations in human melanoma.
Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
[TBL] [Abstract][Full Text] [Related]
18. Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.
Shuai H; Duan X; Zhou JJ; Liu Y; Wu T
BMC Urol; 2023 Nov; 23(1):177. PubMed ID: 37915019
[TBL] [Abstract][Full Text] [Related]
19. An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
Wu Y; Cai D; Fan J; Meng C; He S; Li Z; Zhang L; Yang K; Wang A; Li X; Du Y; Xiong S; Xia M; Li T; Dong L; Gong Y; Zhou L; Li X
Chin Med J (Engl); 2024 Jan; 137(2):232-234. PubMed ID: 37455255
[No Abstract] [Full Text] [Related]
20. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations.
Tornesello ML; Cerasuolo A; Starita N; Amiranda S; Bonelli P; Tuccillo FM; Buonaguro FM; Buonaguro L; Tornesello AL
Front Cell Dev Biol; 2023; 11():1286683. PubMed ID: 38033865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]